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Abstract
Current tissue engineering therapies use macro-scale three dimensional (3D) scaffolds to treat
tissue defects surgically. Uneven cell seeding and oxygen and media perfusion cause low cell
viability in these macro-scale scaffolds. Microencapsulation, a technique of encapsulating cells
in biocompatible polymers or hydrogels, has the potential to address these key issues, and
therefore this technology has been used for numerous healthcare applications over the last two
decades. Cell microencapsulation in hydrogels that mimic the tissue physiology and
biochemistry has made it possible to use natural hydrogels like gelatin methacrylate (GelMA) to
encapsulate cells in microspheres inside an oil emulsion, to serve as micron scale scaffolds to
encapsulate cells for tissue engineering applications. Cell microencapsulation, however, has
challenges with respect to the number of cell laden microspheres that can be achieved repeatedly
with a consistent cell density per microsphere and their ability to achieve and maintain a high
cell viability. This is the major impediment to the clinical translation of cell microencapsulation
to treat tissue defects without surgery. In this work, cells were encapsulated within GelMA
microspheres, ranging 30-250 micrometers in diameter using a 3D printing and replica castingmolding approach. It is a non-clean room fabrication approach and hence a relatively
inexpensive universal platform to encapsulate cells. Rheological properties of varying GelMA
concentration were used to identify optimal concentration, flow rates of the GelMA and oil
phases and the pressures required to achieve the desired size of microspheres with high
repeatability. The success of this approach is demonstrated by high cell viability observed in the
in vitro results. The use of 3D printing makes the fabrication of this microfluidic chip easy,

inexpensive and accessible to biological researchers, and as a result, help lower the barrier of
entry to the field of microencapsulation.
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Chapter 1: Introduction
Scope
This section comprises of an overview of the current challenges in fabrication techniques used
widely in clinical settings for tissue engineering therapy.

1.1 Introduction to tissue engineering
Tissue engineering is a technique of using organ specific cells and seeding them onto support
structures or scaffolds made out of biomaterials. These may be infused with bioactive factors that
assist the viability, differentiation, and proliferation of cells when surgically implanted into the
patient to develop functional organs[1]. Scaffolds or support structures are essential to hold the
cells in a structure inside the body and also to provide a surface of attachment for the cells to
grow and proliferate. Scheme 1 shows the basic concept of tissue engineering therapy. Stem cells
are usually taken from a patient by a biopsy and they are cultured, expanded and seeded onto the
macro scale (mm or cm or inch size) three dimensional (3D) scaffolds. These scaffolds are
incubated in bioreactors that are units that help perfuse cell media, oxygen, and bioactive factors
to assist cell viability, proliferation, and integration of blood supply or vascularization. It is
important that the scaffolds are vascularized to ensure that the cells stay alive in the scaffold.
This incubated scaffold is then surgically implanted into the patient where it should integrate
with the host as the cells differentiate into the specific functional tissues. Most of the approaches
used in clinical tissue engineering therapy involve the use of macro scale scaffolds for seeding
cells. These macro scale approaches involve two main challenges (i) uneven cell seeding
throughout the 3D scaffold and (ii) inadequate oxygen and media perfusion throughout the
scaffolds which could affect cell viability upon implantation[2].
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Scheme 1.Basic concept of tissue engineering therapy[3].

1.2 Overview of cell encapsulation in tissue engineering and current challenges.
Seeding cells on scaffolds have challenges with achieving uniform cell distribution throughout
the scaffold. The idea of cell encapsulation is to encapsulate cells in spheres made out of
biocompatible polymers or hydrogels and seed these cell laden spheres on a three-dimensional
(3D) scaffold. Cell encapsulation has proven to be an effective cell seeding technique to ensure
even cell seeding throughout the 3D scaffold volume [3]. This scaffold can then be surgically
implanted in the patient. The function of a scaffold is to degrade with time while holding the
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encapsulated cells within the organ’s macro structure allowing them to differentiate and
proliferate [4].Cell encapsulation in hydrogels has proved to be an effective cell encapsulation
approach [3]. As shown in Scheme 2, tissue engineering functional organs use cell encapsulation
technologies to ensure even cell distribution and density throughout the scaffold volume. Stem
cells specific to the tissue type are taken from patients and are encapsulated in spheres made out
of biodegradable polymers or hydrogels that mimic the in vivo environment. A large number of
these cell laden spheres are then seeded on scaffolds and this helps ensure a better 3D
distribution of cells throughout the scaffold volume. Since the cells are encapsulated in spheres,
stacking multiple such cell laden spheres give a natural porosity to the macro structure of the
scaffold. This allows better integration of the cells in vivo and ensures optimum room for
vascularization of the construct as the encapsulating hydrogel degrades after implantation.
Encapsulating cells at the macro (cm/mm or inch scale) and micron (less than 500µm) diameter
spheres in different hydrogels like gelatin methacrylate (GelMA) and alginate have shown some
success in the last decade in tissue engineering of liver, heart, cartilage, skin, and bone [5].
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Scheme 2. Cell encapsulation applications in tissue engineering therapy[5]

1.3 Importance of cell micro encapsulation:
Cell encapsulation for tissue engineering therapy can be done both at the macro scale i.e. in
spheres bigger than 500µm in diameter and also at the micron scale i.e. in spheres smaller than
500 µm in diameter. Macro-encapsulation of cells in these hydrogels that mimic the in vivo
environment to support the viability of cells serves as a good cell seeding strategy. However,
scaffolds bigger than 300 μm in dimensions have issues of inadequate media and oxygen
perfusion and inadequate vascularization leading to lower cell viability [6]. It has been
demonstrated in the literature that it is essential to control the microsphere size to an optimal
range to support maximum cell viability. It has been shown in the previous literature that for
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microsphere sizes above 300µm a lower cell viability is generally observed [7]. Sawyer et al.
suggested in their discussion that this could be due to the oxygen diffusion limit which inhibits
cells from getting the necessary nutrition and causes low cell-viability [8]. A precise control over
the size of these hydrogel microspheres plays a critical role in affecting the phenotypic
characteristics like differentiation or induction or gene expression of the encapsulated cells
making this a universal platform technology for stem cell therapy [8][9].Microencapsulation of
cells facilitates the even cell seeding since the hydrogels that encapsulate these cells in micro
spherical emulsions themselves act as micron scale scaffolds. Due to the micron scale of these
hydrogel microspheres, they are easily injectable thus potentially eliminating the need for highly
invasive surgery required to implant larger scaffolds to treat 3D visceral tissue defects [10].
These micron scale structures can be made out of a variety of biocompatible hydrogels with
varying concentration of prepolymer solutions and hence varying degradation rates [11]. This
formed the basis of selecting a micro-encapsulation approach for potential applications in tissue
engineering.

1.4 Existing micro encapsulation techniques and their drawbacks
Microfluidic devices have been extensively used for a wide variety of cell applications. The
ability to study the effects of the microenvironment on cell growth, viability and differentiation
with precision has made microfluidics their own industry with a predicted market value of
billions of dollars [12]. The existing technologies have increasingly used micro encapsulation
due to the small scale encapsulation of cells for a variety of applications in immunology, drug
testing, determining the effects of a variety of biophysical parameters on cell-signaling, motility,
survival, and differentiation [13]. The popular devices used for micro-scale encapsulation of cells
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often require clean room fabrication techniques that are either complex or prohibitively
expensive. Most of these techniques use microfluidic devices for cell encapsulation [14][15]. The
current challenges facing the microfluidic devices used for cell encapsulation on the market are
the complexity of fabrication and their dedication to encapsulate limited cell types [16][17].
Another issue associated with the microfluidic chips that are currently used for cell encapsulation
is the lack of flexibility of the experimental set up with respect to efficiency of sample collection,
microsphere size repeatability, and the number of cells per microsphere [8]. Scheme 3 shows the
existing technologies for micro encapsulation used in laboratory research.

Scheme 3.Existing technologies for cell microencapsulation[5]
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Bulk and hollow: In this approach, the cells are encapsulated in bulk hydrogel blocks or in
hollow hydrogel fibers by pressurizing through a syringe nozzle or block casting of hydrogels.
This is a macro-scale approach, however, can be used at a micron scale by 3D printing micron
scale blocks of hydrogels laden with cells [5].
Micro molding: In these techniques, typically a master mold is fabricated using any lithography
approach with the desired microstructures. The hydrogels laden with cells are pipetted into these
microstructures, cross-linked and removed to yield the cell-laden microstructures [5].
Micro bead/T junction: These are principally microfluidic devices that have two-micron scale
channels that intersect in a T junction. The microencapsulation occurs at the T junction cross
section[5].
Microfiber: This technique uses a capillary based microfluidic design to generate micron-scale
diameter fibers of cell laden hydrogels [5].
Oil drop method is a technique of dropping cell-laden GelMA balls into an oil well so that the
cell laden GelMA balls up into spheres coated with a layer of oil. Another group of widely used
popular microfluidic devices for cell encapsulation employ the oil drop methods that use clean
room fabrication approaches to create hydrogel emulsions which make them prohibitively
expensive [18]. The oil drop techniques used currently do not allow a precise control of emulsion
morphology or the number of cells encapsulated per sphere.

In this thesis work, a flow focusing T junction model is used. Flow focusing T-junction models
are widely used in the synthesis of microspheres using a laminar flow of two immiscible phases
[19][20]. A flow focusing T junction consists of two micron scale microfluidic channels that
intersect at right angles to form a T shaped junction. One of the inlets is for an aqueous phase
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which is usually the hydrogel laden prepolymer solution with cells. Scheme 3 shows the current
flow focusing microfluidic devices and how they are used in cell encapsulation that allow
encapsulating cells in micron scale spheres by controlling flow rates of the aqueous and the oil
phases. The major concern with the existing T junction models was that the lipid phase or the oil
phase used induced a very high shear stress on the hydrogel phase containing cells, which affect
the cell viability that can be maintained [19][18]. For tissue engineering applications maintaining
a high cell viability is of vital importance.

Scheme 4.Microfluidic devices in cell encapsulation[56]

Regardless of the size of the resulting encapsulation constructs, the greatest limitation to the
widespread use of microfluidic setups is their complexity of fabrication [21][22]. This is
especially true for devices used for micron scale encapsulation of cells, which requires the use of
traditional clean room fabrication techniques. Popular photolithography techniques using silicon
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substrates have dimensional limitations and are restrictively expensive[23][16]. Fabrication
techniques employ clean room fabrication approaches to create hydrogel emulsions which make
them prohibitively expensive [2]. Even the oil drop techniques do not allow for a precise control
of emulsion morphology or the number of cells encapsulated per sphere. Other fabrication
approaches for microfluidic devices used for microencapsulation include silicon etching [24],
mechanical micromachining [25], imprinting and hot embossing [26], x- ray photolithography,
laser photo ablation [27], 3D soft lithography [28] and injection molding [29], all of which have
very complicated and elaborate experimental set-ups [30]. In summary, a broad range of
techniques have been used to make microfluidic devices that enable the formation of
microspheres using hydrogel materials. Hydrogels have emerged as an ideal material for cell
microencapsulation studies due to their resemblance to the native extracellular matrix [31].
However, factors such as the method of cross-linking, toxic concentrations of photo-initiators
[32], porosity parameters and storage capabilities also influence cell viability under this approach
[33]. Microfluidic devices for cell encapsulation using fluid flow focusing microfluidic devices
have been used for numerous in vitro assays to study the viability and behavior of cells in micron
scale scaffolds. These devices allow for a precise laminar flow of fluid phases with a wide range
of viscosities, with the ability to manage their flow rates. Along with their dimensions on the
micron scale, microfluidic setups may ensure emulsification of two distinct phases at the cross section of the two channels, resulting in the creation of micro-spherical emulsion structures may
serve as micro-scale scaffolds if the appropriate materials are used. The lack of precise control of
encapsulation dimensions makes this process rigid and inflexible during translation into animal
models for clinical studies. Efforts to improve these draw backs have led to numerous impetus on
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developing fabrication techniques alternative to clean room approaches to fabricate microfluidic
chips and molds.

1.5 Goal of the thesis work: The goal of this work was to engineer a universal microfluidic chip
to enable the encapsulation of cells using a high resolution 3 D printing fabrication approach for
the microfluidic mold to make the cell encapsulation process high throughput and ensure there is
minimum process induced damage and sustained high cell viability.
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Chapter 2: Experimental Design

2.1 Methods and Materials
This section elaborates on the hydrogel synthesis, device fabrication and cell culture protocols
used in the experiments for both the non-cell and cell work.

2.1.1 GelMA synthesis protocol
10 grams of Type A Porcine gelatin were weighed and dissolved in 100ml PBS buffer in a threeprong flask immersed partially in a water bath. The water bath is set to heat a three-prong flask
with magnetic stirs both in, the bath and in the flask. The water bath is maintained at a
temperature of 60-65°C. To remove the oxygen, rubber stoppers were used to block two out of
the three outlets of the three-prong flask. One outlet was left uncovered to account for pressure
buildup. One of the two rubber stoppers were punctured with a needle allowing argon gas to flow
in at 10 PSI for 10 minutes to remove any oxygen introduced during the dissolution of the gelatin
in the buffer. 8 ml of methacrylic anhydride was added very slowly using a 5 ml syringe needle
through one of the rubber stoppers on the three-prong flask. The mixture is allowed to react for 3
hours. After 2 hours 45 minutes 100 ml PBS buffer was warmed up to 60°C for about 15 minutes
to dilute the reaction mixture. 3.5 liters of millipore water was set aside in a large beaker on a hot
plate to warm up to 70°C. A 12-14 kDa cellulose membrane was suspended in this millipore
water bath allowing it to open up for about 10 minutes. One side of the membrane was clamped
and the reaction mixture was poured into the cellulose membrane, clamped up on both sides and
suspended in the millipore water for 1 week. The millipore water was changed every 12 hours
for this one week. The reaction solution was then stored in centrifuge tubes and frozen overnight
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in a -80ºC freezer. These tubes were then put in a lyophilizer and allowed to dry for one week. At
the end of the second week, the GelMA was ready to use to make solutions of different
concentrations. Irgacure 2959 was added to these solutions as a cross-linking photo initiator [34].

2.1.2 Device fabrication
The device was designed on Inventor, a CAD design software. There are two channels
intersecting at right angles to form a T junction. The channel width was defined at 150μm and
the channel height at 2mm.The mold base was a rectangle 8mm in length, 5mm in width and
2mm in thickness. PDMS base and curing agent were hand-mixed well in the 4:1 ratio and
degassed in a vacuum gasket for 30 minutes. The PDMS was poured on top of the mold and
cured in an oven at 60°C for 3 hours to set it. After 3 hours, the PDMS was cut along the edge of
the mold using an xacto knife and peeled out. The peeled portion if the PDMS was the negative
of the mold, which was bonded face down to a glass slide using a plasma cleaner at Dr. Maroo's
lab in Life Sciences Complex, Syracuse University.

2.1.2.1 Design and fabrication of the 3D printed microfluidic device
The negative mold was designed for channel dimensions of 150 μm for both horizontal and
vertical channel width, 4 mm channel height for all channels, the mold base was 4 mm thick and
the mold rim was 5 mm in height. The inlet and outlet rectangular chambers were defined at
0.2234 inches x 0.28 inches (5.67436 mm x 7.112 mm). The chip was then connected to the
inlets as shown in Figure 1.

13

(A)

(B)

Figure 1 (A) 2D Front View and (B) 3D oblique view of the channel dimensions

To fabricate the microfluidic chip the CAD design was extruded and exported as a .stl file to the
Cornell NanoBiotechnology Center (NBTC) at Ithica Cornell University, where it was 3D
printed on a plastic like material called Vero-Clear using the ObJet 30 Pro 3D printer from
Stratasys, Inc. This 3D printed showed a resolution of 16 microns for Vero Clear material (.0006
in.) [35] allowing us to 3D print fine channels with ease. This mold as shown in Figure 2 (A) was
shipped back to our lab at Syracuse Biomaterials Institute, where it was cleaned by submergence
in a solution of KOH 25% w/v solution in 15ml DI water and manual cleaning of the 3D printing
left overs. This cleaning process was repeated three to four times to obtain a clean mold that was
ready for Poly Dimethyl Siloxane (PDMS) casting. PDMS was mixed in the 1:4 ratio of curing
agent to base, poured on the mold, vacuum degassed and cured in an oven at 60˚C for 4 hours.
Then this device was cut with a xacto knife along the edge of the mold and then peeled and
plasma bonded to the glass slide as shown in figure 2(B) using the plasma cleaner facility. The
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plasma radiation time of 1minute 30 seconds was used for each chip at an oxygen pressure of
10psi [36].

(A)

(B)

Figure 2. (A) 3D printed mold (B) Microfluidic device after replica molding and plasma
bonding: (1) Inlet for GelMA phase (2) Inlets for oil phase (3) Outlet.

2.1.3 Set up:
The pump used to drive the encapsulation is the CorSolutions Pneu Wave dual channel pump.
This pump operated on a pressure volume flow principle. The higher the pressure applied the
higher the flow rate. The pump operates in a 0 -120 μl /min flow rate range for pressures from 014.5 PSI. Figure 3 shows the entire experimental setup. The GelMA solution with and/or without
cells flows through the tubing marked 1. The perfluorodecalin oil flows through the tubing
marked 2 in figure 3. The GelMA phase enters the microfluidic chip at inlet marked 4 in figure 3.
The oil phase enters the two inlets marked 3 in figure 3. The sample collection outlets are
marked 5 on the figure. The samples (emulsions with microspheres) are collected through a tube
marked 6 in figure 3. The samples are collected in a petri dish marked 7. These samples are then
UV cross-linked.
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1. GelMA phase flow path
5. Outlet for sample collection
2. Perfluorodecalin oil phase flow path
6. Tube outlet for sample collection
3. GelMA phase inlet
7. Petri dish for sample collection
4. Inlet paths for oil phase
Figure 3. Experimental set up

2.2 Non-cell emulsion experiments:
To test the range of emulsions that could be achieved by this chip, solutions of different w/v
concentrations of GelMA prepolymer were tested for their ability to form UV cross-linkable
microspheres. 3%,5%,7%,8%,10% and 15% w/v GelMA prepolymer solutions were therefore
made. The GelMA prepolymer solution flowed through the vertical channel as shown in Figure 2
(B) (Inlet 1) in the results section of this work, while the oil phase was a fluorinated oil
perfluorodecalin, which has been found to successfully encapsulate hydrogels and assist
osteogenesis in previous research [37].The oil phase flows through the horizontal channels from
both inlets as shown in Figure 2 B (inlet 2) in the results section of this thesis. The two phases
merged at the cross section of the T junction in the chip where the microspheres are formed
inside oil emulsions. These emulsions containing microspheres then flow out through the exit
channel and are collected out of a needle from the exit channel. The volume of a single emulsion
is typically 20μl that contains around 4510 microspheres. The emulsions were collected as
subsequent squirtings in a petri dish and irradiated with UV-light (Output power 850 mW, Omni
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Cure S2000) for different exposure times corresponding to different concentrations of GelMA.
To make the chip a universal platform for encapsulating all clinically relevant cell types, a
threshold of the 250 x 250μm2 cross sectional area was implemented. This resulted in
microspheres ranging from 30 μm to 250 μm for different flow rate ratios and concentrations, the
specifics of which are listed in the results section of this literature.

2.2.1 Viscometric characterization
An AR-G2 Rheometer (TA Instruments, New Castle, DE) was used to obtain the viscosity at
high shear of prepolymer solutions of varying GelMA concentrations. A parallel plate setup was
used with a 40mm diameter steel geometry serving as the top plate. An implemental heating
plate (522310.902 Peltier plate assembly) was used as the bottom plate to ensure the tests were
performed at 37oC to replicate experiment conditions and prevent thermal gelation of the
solutions. 2 ml of prepolymer solution was carefully pipetted at the center of the heating plate. A
gap of 1.5 mm was maintained. The temperature was equilibrated for two minutes, after which
the samples were subjected to a steady state flow procedure where the shear rate was ramped
from 0.1 – 1000 s-1.

2.2.2 Rheological Characterization
An AR-G2 Rheometer (TA Instruments, New Castle, DE) with a parallel plate geometry (8 mm
diameter) was used to determine the viscoelastic behavior of cross-linked hydrogel samples made
from solution of different polymer concentrations.
300 µl of each prepolymer solution was injected between two 18 x18 mm glass coverslips
(Globe Scientific, Paramus, NJ) separated by a custom-printed PLA spacer with 1mm thickness.
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Samples were then irradiated with UV for 60 seconds (Output power 850 mW, Omni Cure
S2000). An 8 mm diameter biopsy punch (Robbins Instruments, Chatham, NJ) was used to cut
out the hydrogel discs and detach them from the cover slips. The hydrogels were then incubated
in ion-exchanged and distilled water at 37ºC for 24 hr prior to characterization to remove any uncross-linked gelatin prior to characterization. Rheological analysis was performed at room
temperature using a gap size of 850 µm. Frequency sweeps (0.1-100Hz) were performed at 1%
strain to identify the behavior of the storage and loss moduli of the constructs. The intersection
point between the two data trends was noted.

2.2.3 Injection experiment
To test whether the obtained GelMA microspheres were stable when injected in and out of a
syringe needle, 100µm and 150µm sphere sizes were tested. The pressure was scaled to obtain
flow rates of 62.5µl/min for GelMA phase and 89.32µl/min to obtain an average sphere size of
100µm repeatedly with good consistency. The flow rates of 72µl/min and 95.26µl/min were used
to yield an average sphere size of 150µm with good consistency; both for 8% GelMA
concentration in 13mL of PBS buffer. These samples were UV cross-linked (output power 850
mW, Omni Cure S2000) for 90 seconds and suspended in DI water. A bright field image was
taken before these spheres were sucked into the 23-gauge needle with a mean diameter of
641.35µm. Then another image was taken after these spheres were injected out of the needle,
after which these spheres were suspended in 20µl of DI water.
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2.3 Cell Experiments:

2.3.1 Step 1: Component sterilization: Autoclaving
To ensure that the encapsulation occurs in a perfectly sterile environment we autoclaved all the
tubing that came in any contact with the cell solution. The fittings and connectors like the luer
locks, Y- junctions and inlet and outlet hoops were soaked in 100% cell culture grade ethanol in
a biosafety hood under UV light to sterilize, as autoclaving damages them due to their lower
temperature thresholds. The microfluidic chip was autoclaved as well to prevent any bacterial
contamination of the GelMA emulsions within the chip. The autoclaving temperature was set at
120°C, where the tubing was autoclaved for a 30-minute cycle and the oil autoclaved for another
30/30 cycle. Autoclaving the tubing, devices and the oil is essential to ensure there is no bacterial
contamination [38].

2.3.2 Step 2: Making GelMA prepolymer solution
To make GelMA prepolymer solutions, a desired volume of buffer is filled in a centrifuge tube.
For most of the experiments 13 mL of buffer were used to make the prepolymer solution. An
appropriate amount (desired w/v concentration) of frozen GelMA polymer was weighed and
dissolved in the buffer. To enable crosslinking 0.25% Irgacure 2959 photo initiator was added.
This weight/volume ratio of 0.0025 was critical and has been found to work for previous
research groups [2]. The centrifuge tube was then stored in an incubator at 37°C and left
overnight to ensure that the GelMA dissolved completely and was adequately degassed before
being sterile filtered.
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2.3.3 Step 3: Making the Cell solution
The GelMA prepolymer solution was sterile filtered using a non-pyrogenic Corning Incorporated
28 mm micron membrane syringe filter (28 mm 0,20 SFCA) into a sterile centrifuge tube to
ensure there is no bacterial or process induced contamination in the GelMA prepolymer solution.
The vile containing the suspended cells is removed from the incubator and the old media is
aspirated. The cells are then trypsinised.

2.3.3.1 Cell Solution protocol
Take 250 mL Saos-2 cell flask out of incubator. Under hood, use vacuum to remove DMEM
(Dulbecco's Modified Eagle's Medium) media from the flask. Fill the flask with 10 mL of PBS
(Phosphate Buffered Saline) to remove excess media. Vacuum out PBS. Add 5 mL of trypsin.
Place flask back in incubator for 5 minutes. Remove flask after 5 minutes and tap the sides of the
flask to detach the remaining cells from the bottom of the flask and into the trypsin solution. Add
15 mL of media to the flask to counteract the trypsin. Mix well, and transfer the
trypsin/media/cell solution into a 50 mL tube (should have 20 mL of solution). Take 10 µL of the
solution and place it in one well of a 64 well plate. In the same well add 10 µL of Trypan blue
dye. Mix and place 10 µL of the dye solution under the glass slide on the Hemocytometer. Take
the 50mL tube and place it in the centrifuge across from a 50 mL tube filled with 20 mL DI
water (for balance). Centrifuge at 200 rpm for 10 minutes. While centrifuge is running, count
cells using 40x microscope and a clicker (ex. Yield 10 million cells). Also, while centrifuge is
running, sterile filter 13 mL of GelMA (you will most likely get 11 mL post sterile filter) into a
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15mL tube. Set GelMA aside. Retrieve 50 mL tube with solution in it from centrifuge and
vacuum the media out (you should see the cells congregated at the bottom.) Add of media to the
50mL tube with just the cells in it and mix (ex. this will give you 10 million cells per 1 mL of
media.) Transfer this 1 mL of cells/media into the 15 mL GelMA tube and mix well [2].

2.3.3.2 Osteosarcoma Cell culture
Human osteosarcoma cells (Saos-2; ATCC) were used for cellular encapsulation studies[2].
Saos-2 cells were cultured in Dulbecco’s Modified Eagle’s Media (DMEM; Life Technologies)
supplemented with 1% penicillin-streptomycin (PS, Life Technologies), 1% GlutaMAX (G, Life
Technologies), and 10% fetal bovine serum (FBS lot G12102, Atlanta Biologicals), within a
humidified 37°C incubator containing 5% CO2 [2]. Prior to encapsulation, cells were grown to
confluence and passaged using 0.25% trypsin-EDTA (Life Technologies). Cells were
encapsulated in GelMA by mixing 1 mL of a cell solution density of approximately 6 million
cells with 10 mL of 8% (w/v) GelMA solution[2]. The GelMA/cell solution was mixed
thoroughly prior to encapsulation and was kept warm throughout the process. After
encapsulation, oil emulsions containing GelMA microspheres were transferred into cell culture
media. Media was changed on the emulsions every 2 to 3 days using standard cell culture
procedures[2].

2.3.4 Step 4: The encapsulation process
The solution contain suspended Saos-2 cells in GelMA prepolymer solution was flowed through
the vertical channel of my chip. The oil phase consists of a fluorinated oil perfluorodecalin[37]
that is found to assist bone regeneration as well as found success in previous encapsulation
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studies. The oil phase flows through both inlets of the horizontal channel. The two fluid phases
intersect at the T junction where there is formation of the emulsion spheres. The cross –sectional
area of the T junction is 150 x 150 μm2. This size allows creation of stable emulsion spheres
ranging from 20 to 250 μm in diameter. This allows immense flexibility in the number of cells
that we can encapsulate in each emulsion sphere. These emulsions flow out through the vertical
exit channels where they flow out through a needle inserted in the exit channel. These emulsions
were collected in petri dishes and then UV cross-linked for exposure times varying according to
the concentration of GelMA in each solution. The UV crosslinking times observed for
5%,7%,8%,10% and 15% w/v solutions were all under 120 seconds which is conducive for
crosslinking GelMA without killing cells encapsulated within. These encapsulated cross-linked
samples were then transferred to a 24-well plate in the biosafety hood. They are then stored in
1mL complete DMEM media in the incubator to ensure cell viability before staining.

2.3.5 Staining:
2.3.5.1 Live/ dead staining:
Live/Dead staining and image processing:
The viability of cells was determined using a Live/Dead assay. In order to determine cell
viability, emulsions containing cell-laden spheres were submerged in media containing CalceinAM (1:2000 dilution; Corning) and ethidium homodimer (1:500 dilution; Life Technologies),
and incubated at 37°C for 1 hour prior to imaging [2]. Emulsions were analyzed at 1 day, 1
week, 2 week, and 3 week time points, respectively.
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Raw .tiff fluorescent images were taken of the stained emulsions using a Leica DMI4000 B
inverted microscope (Leica Microsystems GmbH), and were analyzed using open-source ImageJ
(NIH) software. The images were tuned for brightness and contrast.
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Chapter 3: Results and Discussion

3.1 Non-cell GelMA microsphere synthesis:
Figure 4 (A) shows the microspheres obtained for flow rates of 35 μl/min for GelMA phase and
50 μl/min for oil phase which generated microspheres of ~33 to 35 μm. The UV cross-linking
time observed for different concentrations of GelMA solutions was recorded and reported in
Figure 4 (B) Table 1. Through experiments, it was observed that it is possible to fabricate
GelMA microspheres with an optimal UV cross-linking time and viscosity efficiently and with
maximum repeatability for 5 to 15% w/v GelMA concentrations. It was observed that for less
than 5% GelMA concentration, the UV cross-linking time required is over 3 minutes which
would be lethal for encapsulating cells in these microspheres and it is also very difficult to
crosslink lower than 5% w/v concentrations of GelMA.

(A)

(B)

Figure 4. (A) GelMA microspheres 35µm in mean diameter made from 8% (w/v)
GelMA (Scale bar: 50 µm) and (B) Table 1. Representing UV crosslinking time for
crosslinking microspheres made from different (w/v) concentrations of GelMA.
Different flow rate ratios of the GelMA phase and the oil phase yield microspheres of different
mean sphere sizes. With this microfluidic chip, it was possible to create microspheres 35 to 250
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µm in diameter with maximum repeatability. Table 1. shows the different flow rates used for the
GelMA phase and oil phase to obtain different sizes of microspheres. The standard deviation
values are low indicating a high degree of uniformity achieved in the obtained microspheres.
The results of this experiment indicate the range of GelMA concentrations that is optimal to
effectively make injectable hydrogel microspheres to serve as scaffolds of micro scale that can
potentially encapsulate all clinically relevant cell types. Figure 5 (A) Table 1 represents the
average size of GelMA microspheres achieved with 8% (w/v) GelMA solution at varying flow
rates. Each solution concentration flowed at three district flow rate ranges and it was observed
that varying these values resulted in microspheres of distinct sizes. As an example, the following
trends were observed for the 8% (w/v) GelMA phase and the standard oil phase respectively. For
flow rates of 45.725 µl/min for GelMA phase and 75.68 µl/min for oil phase (8% w/v GelMA
concentration), repeated microsphere mean size ~50 μm-corresponding to these flow rates. For
flow rates of 65.27 µl/min for GelMA phase and 89.32 µl/min for oil phase (8% w/v GelMA
concentration) repeated microsphere mean size ~100 μm corresponding to flow rates. For flow
rates of 72.67 µl/min for GelMA phase and 93.76 µl/min for oil phase (8% w/v GelMA
concentration) repeated microsphere mean size ~150 μm-corresponding to the flow rates. After
repeating these trials, these values were found to be consistent.
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50µm

100µm

150µm

(A)

(B)

Figure 5. (A) Table 2. Different mean microsphere sizes achieved using
different flow rates and (B) Representative images of 50,100 and 150µm
microspheres. Scale bar: 150µm

3.2 Characterization of material properties:
The hydrogel used for cell microencapsulation in this work was tested for different w/v
prepolymer solution concentrations. The viscous and rheological properties of these prepolymer
solutions were characterized. Figure 6 (A) represents the viscosity profiles of different (w/v)
GelMA prepolymer solution concentrations. The viscosity varies as the shear rate on the parallel
plate is varied from 1 to 1000 s -1. Non-cell experiment work was necessary to optimize
conditions and characterize our materials. Physical characterization was centered on observing
the hydrogel storage and loss moduli for different concentrations of GelMA. Figure 6 (B)
represents the storage and loss modulus of an 8% (w/v) cross-linked hydrogel disc. This was
done to approximate the stiffness of the matrix environment experienced by the cells once in
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their encapsulated form. Solution viscosity was a focal point of study [39] to identify the
maximum concentration that could be used that would optimally flow through the setup at the
high flow rates to be used, especially since the laminar flow was required to effectively form our
microspheres. The temperature and the flow rates corresponding to this shear rate were
determined to be the thresholds (minimum flow rate) required to form emulsions at these
solution concentrations. To quantify the mechanical nature of microspheres made out of these
pre-polymer solution concentrations, rheological characterization of the loss and compression
modulus was done [40]. A comparison of the viscous and mechanical properties of varying w/v
concentrations of GelMA helped us determine the w/v concentration range and narrow down on
the GelMA concentrations that work best for cell encapsulation experiments that are discussed in
the following section.

(A)

(B)

Figure 6. (A) Viscosity profiles of different (w/v) GelMA concentration prepolymer
solutions and (B) Storage and loss moduli for 8%(w/v) GelMA slab

Microspheres of specific dimensions were expected to show unique swelling behavior which is
shown in Figure 7. Figures 7(i - iii) represent the swelling observed for 3 repeatedly achieved
microsphere sizes using 8% (w/v) GelMA. It was observed that the microsphere with 50μm
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initial mean diameter saw a 35.01% increase in diameter. Samples with a 100μm initial mean
diameter saw a 16.54% increase in diameter, while the larger microspheres with a mean diameter
of 150 μm initial mean diameter also saw a small increase in diameter but only of about 8.6%
after complete swelling. For all tested samples, it was observed that the completely swelled state
was reached after about 2 hours 30 minutes, after which no significant change in dimensions was
observed. The stepwise mean %increase and standard deviations are listed in a table in the
Appendix A Section C of this work.

(i)
50µm
(ii)

100µm
(iii)

150µm
(A)

(B)

Figure 7(A) Swelling profiles: %increase in mean microsphere diameter as observed with
time and (B) represents the before and after swelling images of 50,100 and 150µm mean
sphere sizes. Scale bar :150µm
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The overall range of microsphere diameter achievable with this microfluidic chip using this twovariable experimental set up was ~30 to 250 μm. Figure 8 represents the before and after
injection images for a 20 µl emulsion volume of 100 µm mean sphere size. There was no
disruption of the microsphere size observed upon injection in and out through a 20-gauge needle.
There was some disruption in microsphere shape observed upon injection through a 23-gauge
needle for a mean microsphere size of 100µm.

(A)

(B)

Figure 8. (A) and (B) Before and after injection images of 100µm GelMA microspheres
through a 20-gauge needle. Scale bar: 100µm

Figure 9 represents the average number of microspheres of 50,100 and 150 μm mean sphere size
per μl of emulsion volume. The microspheres are laden in an oil emulsions which were ejected as
20 microliter emulsions from the outlet of the microfluidic chip. This table and graph give an
estimate of the number of microspheres obtained per unit volume of an emulsion.
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(A)

(B)

Figure 9. (A) Graph and (B) Table 3. Representing average number of microspheres per µl of
emulsion volume

3.3 Cell Encapsulation experiments
A solution concentration of 8% (w/v) GelMA was selected for all cell encapsulation work based
on all these studies. The viscosity of this prepolymer solution was shown to exhibit laminar flow
through the pump setup when at 37oC most efficiently, which is the required temperature to
maintain cell viability. The UV exposure time required to cross-link the resulting microspheres
was also low enough to ensure that this viability was maintained. The constructs also exhibited
structural stability when incubated for three weeks. Figure 10 (A) shows a single emulsion sphere
100 μm in diameter with cells encapsulated within. The image was taken after performing the cell
encapsulation experiment when the microsphere was in media. The image is taken at 40x bright
field using an inverted microscope. It was observed that larger microspheres encapsulated a greater
number of cells. Figure 8 (A) and (B) shows ~28 cells encapsulated in a 100 μm sphere in media
and oil respectively.
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Figure 10. Single microsphere cell encapsulation images.100 μm sphere with cells
encapsulated (A) in media and (B) in perfluorodecalin oil. Scale bar:100 μm

Figure 11. (A) Represents the number of cells encapsulated in spheres of different sizes. The
number of cells that can be encapsulated increases with an increase in the size of the
microsphere. The 100 μm sphere as shown in Figure 11 (A) has around 28 cells encapsulated
within. The cell concentration plays a key role in determining the cell encapsulation density per
microsphere. The cell density that proved most effective was 6x106 cells per 1 ml cell media
added to 11 ml i.e. 545,454 cells/ml GelMA prepolymer solution after sterile filtering. Different
cell densities dictate how much volume of each microsphere is occupied. This also largely
depends on the cell dimensions or the shear rate used. In this setup, we used Saos-2 cells which
are approximately 8-10 μm in diameter [41]. Through our experiments, we identified that for cell
densities greater than 545,454 cells per ml cause excess shear stress on the cells when they flow
through the tubing that leads up to the device inlet. Figures 11 (A) and (B) represent the number
of cells encapsulated per microsphere of different mean microsphere diameters. It is evident from
the graph that as the mean microsphere diameter increases, the number of cells encapsulated per
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microsphere increase. A test of significance for correlation coefficient was performed on this
data and it was found that there is a significant correlation between the microsphere mean
diameter and the number of cells encapsulated.

Figure11. (A) and (B)Table 4 and graph representing the average number of cells
encapsulated per microsphere for different mean microsphere diameters

Figure 12 represents the %Viability of cells as observed for 100 μm spheres on Day 1, Day 7,
Day 14 and Day 21. We observed a cell viability of 98.03% on Day 1 indicating that this process
is fairly mechanically robust and biocompatible enough to not introduce a significant process
induced damage or contamination. A viability of 93.75% on Day 7, 90.125% on Day 14 and
81.25% on Day 21 was observed. The Figures 12 (i), (ii) and (iii) show the actual live /dead
staining progression from Day 7 through Day 14 to Day 21. An ANOVA analysis was performed
on this viability data which is listed in the Appendix A Section D section of this thesis, which
reaffirms the visually obvious significant difference in the cell viability over the three week
incubation period. Cell density plays a key role in determining the cell encapsulation density per
microsphere. The cell density that proved most effective for our trails was 6x106 cells/mL of cell
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media added to 10mL GelMA prepolymer solution (11mL total). Different cell densities dictated
how much volume of each microsphere was occupied. Limited process-induced damage was
observed as cell viability remained close to 100% immediately following the procedure.
Incubation over a three-week period showed that viability only decreased by ~20%. This shows
that our encapsulated cell samples may be stored without the need for cryopreservation. Cell
density was also shown to play a role in influencing cell viability. Densities higher than the 6
million cell count was shown to cause a decrease in cell viability when encapsulated. Additional
factors such as cell size and applied shear stress resulting from an increased cell density during
the encapsulation procedure would be expected to play a role in cell viability when using other
cell types. We can therefore assume that use of larger cell strains may exhibit a different viability
profile as oppose the Saos-2 cell quantified for this work, and therefore we may need to optimize
an appropriate cell density to achieve the similar viability statistics.
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(i)Day 1

(iii)Day 14

(ii)Day 7

(iv)Day 21

Figure 12. (i)Day 1, (ii)Day 7, (iii) Day 14 and (iv) Day 21 viability (Scale bar
:100µm). (A) Percentage viability as quantified on day 1, day 7, day 14 and
day 21. (B)Table 5 representing average percentage viability and
corresponding standard deviations.
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Cell viability depends on the coordination between multiple parameters. The GelMA
concentration used, the cell density used, the viscosity of the solution, and the temperature of the
experimental set up. These were identified by experimenting with multiple GelMA
concentrations, cell densities starting from 10 million cells and decreasing and adjusting the
temperature and distance of the heating fan used to maintain the temperature of 37 °C. Also, it is
essential to ensure that all the tubing, connection, devices and collection petri dishes are either
autoclaved or sterilized by soaking them in 100% fill line ethanol to make sure that there is no
contamination or process induced damage to the cells.
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Chapter 4: Discussion, conclusion and future scope

4.1 Discussion
This section represents a comparison of existing cell micro encapsulation approaches and the
improvement over the existing techniques in the aspects of fabrication approach, cell viability,
high sample collection efficiency, high microsphere size repeatability and uniform number of
cells laden per microsphere. The results presented in this work have shown a significant
improvement over certain impediments to the existing cell micro encapsulation approaches over
factors of (i) fabrication approach, (ii) cell viability, (iii) high sample collection efficiency, (iv)
high microsphere size repeatability and (v) uniform number of cells laden per microsphere. The
mold used to cast the microfluidic devices was fabricated using a 3D printing fabrication
approach and PDMS casting and molding technique.

4.2 Research approach
The novelty of this design allows immense flexibility of the size of microspheres that can be
made and used to encapsulate a varying number of cells per microsphere depending on the cell
density used in your cell solution and the size of microspheres. Due to the small size of achieved
microspheres, they are injectable and hence can potentially help eliminate the need for surgery
[42].This engineered chip enables micron scale encapsulation of all clinically relevant cell types
in emulsion spheres ranging 30 to 250 μm in size. Due to the small size and range of
encapsulation, effective media and oxygen diffusion is possible, thereby showing enhanced cell
viability as demonstrated in my results. The flexibility in choosing varying concentrations of
GelMA to encapsulate cells allows control on properties like swelling and degradation of the
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hydrogel microspheres. Also, there is control of parameters like viscosity and mechanical
robustness of the used hydrogel concentrations. To support and hold the cells in place it is
essential that they are seeded inside a support structure or a scaffold. Many times, cells do not
get evenly seeded in the scaffold. The microspheres generated by this chip allow the creation of
cell laden microsphere scaffolds which ensure adequate and even cell seeding all throughout the
size of the injury or defect which needs the tissue engineered construct [43]. Due to their small
size, these microspheres can be injected at the site of tissue injury without the need for imminent
surgery. This exciting hypothesis is what has led to the application of microencapsulation
approach for this work.

This approach of micron scale encapsulation in hydrogel makes it a lot easier to preserve these
micro-scale scaffolds in a normal well plate in an incubator instead of cryopreserving the
construct. Cell viability is determined by a variety of parameters: toxicity and the amount of
photo initiator [44], the degradation rate of encapsulating hydrogel, cell media and oxygen
perfusion, porosity and interconnectivity of the scaffold, cryopreservation, storage requirements
and the duration of storage [33][45]. The system designed in this work proposes a highly flexible
and customizable technique to create hydrogel droplet scaffolds that resize all such parameters to
help achieve enhanced cell viability. The PDMS based closed chip is made out of a 3D printing
[46] and replica molding [47] approach which ramps up the ease of fabrication to your lab bench.
Being an inexpensive polymer, you can make a large number of these chips and use them for
encapsulation applications of various kinds of studies. This work presents an inexpensive
microfluidic chip fabricated through 3D printing [48] followed by a replica casting and molding
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technique [49]. The system designed proposes a highly customizable technique to create
hydrogel droplet scaffolds that resize all parameters to help achieve enhanced cell viability.

4.2.1 Fabrication approach:
Popularly used microfluidic devices are manufactured using micromachining approaches with
glass or silicon substrates. These micromachining approaches involve processes like chemical
etching, lithography approaches that require a clean room for cleaning processes. Laser ablation
approaches that need the use of high intensity laser beams to micro machine channels in different
substrates. Other techniques like hot embossing, injection molding require thermoplastic
substrates that have heat expansion related dimensional changes in the channels which impact
the generated microsphere sizes and uniformity which varies with temperature [50]. In this work,
the negative to the closed PDMS chip is made using a traditional 3D extrusion printing [51] and
replica molding approach, which ramps up the ease of fabrication of multiple devices. In using
Vero-clear plastic [52], an inexpensive polymer, multiple chips designs can be made on a budget
and used for encapsulation applications for a wide variety of studies. It should be noted that for
objectpro30 3d printer model RGD525, RGD430 and RGD450 [53] polymers can also be used in
the printing process [35]. The use of PDMS as a casting agent facilitates the manufacture of
multiple devices from a single print. After a careful deliberation of choice of 3D printing
polymer and vertical resolution and ease of use and access, we decided to go ahead with the
Stratasys Objet Pro30 model desktop size 3D printed to fabricate the microfluidic device used for
microencapsulation in this work. The use of GelMA over synthetic hydrogels like PEG-DA has
significantly increased over the past decade in cell microencapsulation applications [54] [55].
Natural hydrogels like GelMA are highly hydrated and porous like tissues making them a highly
biocompatible choice to house cells.
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4.2.2 Comparison cell viability in different micro encapsulation techniques:
Multiple studies have been done to microencapsulate different cell lines and the viability of cells
was monitored over different time frames.In using laminar flow model, for cell microencapsulation
Kim et.al. demonstrated that the cell viability varied in proportion to the flow rate of the oil phase
[56]. In that work, the viability was observed for over seven days and on 60% of the cell population
was alive [56].
Kim et al. showed the viability of encapsulated fibroblasts in GelMA using a double flow focusing
microfluidic chip design. The viability was monitored for over 10 days and was up to 80%.This
approach revealed that cytotoxicity of the oil used for cell microencapsulation and position of cells
during encapsulation process played a key role in determining process induced damage and
corresponding viability monitored over a 10 day period [56].
Weitz et al. demonstrated a 60% cell viability one day after encapsulation of microencapsulated
bone marrow derived mesenchymal stem cells (BMSCs) in gelatin microspheres. Although the
cells showed improved osteogenesis in vitro and in vivo in the encapsulated gelatin
microspheres, the process induced damage was concerning [57][58].The results of this work
show a far better cell encapsulation density per sphere and a wider range of repeatable
microspheres achieved.
Rossow et al. also demonstrated that after 1 day of encapsulation in GelMA microspheres they
achieved a viability of only 60% [57] whereas the approach of the research stated in this
literature demonstrates a very high cell viability of 98.03% on Day 1 indicative of minimal
process induced damage.
Work done previously in the Soman lab by Sawyer et al. monitored the viability of Saos-2 cell
encapsulated in 7%,10% and 15% w/v GelMA concentrations in 5 mm GelMA macro spheres.
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The viability observed was ~70% for 7% GelMA concentration, and close to ~50% for 10% and
~40% for 15% (w/v) GelMA concentrations. This is concerning because Saos-2 cells are a robust
cancer cell line. If this approach were to be used to encapsulate clinically relevant stem cells
which are more sensitive, a low viability would hamper successful translation for clinical tissue
engineering therapy. In the discussion of their work Sawyer et al. mentioned that a low cell
viability was expected as cells are encapsulated in 5 mm spheres that are beyond the diffusion
limit of 300 µm as suggested in previous work [7][2]. A microencapsulation approach would
help encapsulate cells within this suggested diffusion limit which forms the basis of the work
presented in this literature.

4.2.3 High sample collection efficiency and high microsphere size repeatability
In a review by Rossow et al. problems associated with sample collection and the repeatability of
the microsphere sizes are highlighted [56]. It was reported that the shear forces acting on the
cells in the aqueous phase may cause process induced cell death which is a major concern. The
transfer of the cell-laden micro gels into the oil phase must be as gentle as possible. This is not
possible with higher flow rates and narrow device dimensions. The cytotoxic chemicals or the
physical processes of pipetting used to break up emulsions can also cause cell death if the used
chemicals are cytotoxic [58][57]. In this work, the channel height used is significantly taller than
other designs which likely prevented high shear stress leading to low process induced damage.
However, no simulation studies have been done to quantify the shear stress experienced by cells
flowing through this device.

40

4.2.4 Repeatability of the number of cells encapsulated per microsphere
Research by multiple groups has shown that encapsulation of cells in micro gels is a stochastic
process and not all generated microspheres are laden with cells[59][60][61]. It was observed that
around 86 out of 100 microspheres should be empty and only 1 droplet should contain more than
one cells for single cell encapsulation[59][60][61]. The statistics vary and controlling the number
of cells encapsulated per microsphere, has been a pressing challenge faced by microfluidic
devices designed for cell microencapsulation [59][60][61].
The system designed in this work proposes a highly flexible and customizable technique to
create hydrogel droplet scaffolds that resize all parameters to help achieve enhanced cell
viability. The novelty of this design allows immense flexibility in the nature of the microspheres
produced. Experiments have identified a range of parameters to relate emulsion size to both
experimental flow rate and solution viscosity and concentration. This design enables varying the
number of cells per emulsion sphere depending on the cell density of the solution used based on
the cell concentrations used.
The flexibility in choosing varying concentrations of GelMA to encapsulate cells allows control
on properties like swelling and degradation of the hydrogel microspheres [62]. Also, there is
control of parameters like viscosity and mechanical robustness of the used hydrogel
concentrations. To support and hold the cells in place it is essential that they are seeded inside a
support structure or a scaffold. Many times, cells do not get evenly seeded throughout the
scaffold. The microspheres generated by this chip allow the creation of cell laden hydrogel
emulsions which themselves serve as micron scale scaffolds. This can ensure adequate and even
cell seeding all throughout the size of the injury or defect which needs the tissue engineered
construct when a large number of these cell laden scaffolds can be injected for therapy.
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This engineered chip can potentially enable micro –scale encapsulation of all clinically relevant
cell types in microspheres ranging 30 to 250 μm in size. Traditional tissue engineered constructs
greater than 300μm in size have shown persistent challenges with oxygen and media diffusion,
reflected in poor cell survival [2]. Due to the small size and range of encapsulation, effective
media and oxygen diffusion is possible thereby showing enhanced cell viability. Additional
procedural parameters are also controlled to ensure continued cell viability, ensuring no processinduced loss.
Rossow et.al had shown that micro encapsulation using PDMS devices fabricated using standard
lithography approaches, led to microspheres 50 to 100 μm in mean diameter in which 86 out of
100 microspheres were empty and only one microsphere should contain more than one cell [57].
The small size of our resulting GelMA microspheres opens up the possibility for multiple clinical
applications. Due to the small size of achieved emulsions, they are injectable, eliminating the
need for invasive surgical procedures for their application. Most constructs must be
cryopreserved until their time of use, a step which strongly hinders their viability [63]. This
remains a major challenge in translating these macro-scaffolds into human clinical trials. To
overcome some of these limitations, micro scale encapsulation can be used. In
microencapsulation, the microspheres can be simply stored in media in a well plate in an
incubator as the encapsulating hydrogel itself acts as a micron scale scaffold. Most crucially,
however, traditional approaches require very rigid experimental setups to achieve successful
microsphere formation and subsequent cell encapsulation.
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It is also observed that this micro-scale encapsulation in hydrogel makes it a lot easier to
preserve these micro-scale scaffolds in a normal well plate in an incubator instead of
cryopreserving the construct. As an extension of this approach as a future application, we could
potentially use these injectable microspheres in an animal model to study the growth of tissue
engineered constructs in vivo and compare results with other research groups as we have better
cell density per unit microsphere volume.
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4.3 Conclusions
Prolonged cell viability is a critical and poignant issue facing current tissue engineered
constructs. This approach of cell micro encapsulation [64] using a non-clean room, 3D extrusion
printing approach, serves as an inexpensive technique to make this happen. The dimensions of
the microspheres allow them to be injectable and can be used as a way to avoid surgical opening
up as required during implantation of other macro scale scaffolds. Even cell seeding throughout
the tissue injury or defect is ensured due to the precise control over cell density as observed in
vitro. The micro spherical shape of these cell laden constructs gives them good porosity and
interconnectivity [65] when injected on top of each other. This could assist vascularization and
ensure sustainability and efficient integration of the cells upon microsphere degradation. These
microspheres have exhibited mechanical robustness and stability for up to 4 weeks with no
visible degradation which makes them viable as scaffolds for tissue engineering applications
with a potential to encapsulate clinically relevant cells. Reiterations of the experiments and
viability studies have shown that this device is able to produce cell laden microspheres with
minimal process induced damage. Moreover, the major advantage of this technology is the
immense flexibility of experimental parameters that allows the use of all clinically relevant cell
types for numerous types of tissue engineering applications. The use of 3D printing helps lower
the barrier of entry to the use of microfluidic technology for other non-specific applications.
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Appendix A

A. Supplementary Information

Figure 13. Fluores brite fluorescence beads encapsulated in an oil
emulsion. Scale bar:100µm

Figure 13 represents 10 μm Fluores-brite YG polyethylene fluorescence micro beads
encapsulated in an emulsion of perfluorodecalin oil. This was an initial primary experiment to
test the chip functionality and its ability to encapsulate micron scale samples. This image was
taken using an inverted fluorescence microscope at 5X. This experiment demonstrated the
efficiency and range of flow rates required to achieve bead encapsulation which by extension
helped me figure out how to enable cell-encapsulation going further. Figure 14 (i) and (ii) show
degrading non-cell laden 100 μm and cell laden microspheres on Day 27 and Day 29
respectively.
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(i)

(ii)

Figure 14. Degradation of a microsphere as observed on (i) Day 27 and (ii) Day 29
respectively. Scale bar:100µm

We took bright field images of the microspheres for day 21 and day 27 to see how much they
degrade over time. The onset of considerable degradation is seen post the three-week incubation
period in PBS buffer for non-cell and DMEM media for cell-laden microspheres. The
microspheres stayed stable for over 3 weeks with high cell viability.
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B.

Scheme 5. The sketch represents our final microfluidic chip dimensions that were used to obtain
all our results consistently. The change in this device design was mainly in its channel height.
The goal of this work was to engineer a microfluidic device that can be used to engineer
emulsion microsphere using a laminar flow of two immiscible phases.
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C. Injection experiment with a 23-gauge needle:

(A)

(B)

Figure 15 (A) Before and (B) After images 20x from injection of 100µm 8%w/v GelMA
microspheres using a 23-gauge needle (Scale bar: 500µm)

(A)

(B)

Figure 16 (A) Before and (B) After injection 5x 20µl emulsion of 100µm of 8%w/v GelMA
using a 23-gauge needle (Scale bar: 500µm).
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D. Swelling profile data details and variations observed

Time
(Minutes)

Average %
Change
(Size 35)

Average %
Change
(Size 50)

Average %
Change
(Size 80)

Average %
Change
(Size 100)

Average %
Change
(Size 150)

15

4.27

4.01

2.51

1.60

1.46

30

7.93

7.21

4.07

2.93

2.36

45

11.68

11.10

5.27

4.14

3.04

60

14.93

15.56

6.93

5.26

3.94

75

18.89

19.13

7.99

6.57

4.81

90

24.60

24.24

10.08

8.30

5.38

105

29.51

27.29

11.46

9.83

6.14

120

38.05

30.08

12.71

11.84

6.93

135

45.63

31.90

13.60

14.01

7.79

150

50.01

34.07

13.60

15.33

8.48

165

53.66

35.00

13.60

16.41

8.60

180

54.95

35.01

13.60

16.54

8.60

195

54.99

35.01

13.60

16.54

8.60

210

54.99

35.01

13.60

16.54

8.60

225

54.99

35.01

13.60

16.54

8.60

Table 6. Average percentage increase in mean diameter of microspheres of different sizes
(Swelling behavior)

Time
(Minutes)

Standard
Deviation
%Change
(Size 35)

Standard
Deviation
%Change
(Size 50)

Standard
Deviation
%Change
(Size 80)

Standard
Deviation
%Change
(Size 100)

Standard
Deviation
%Change
(Size 150)

15

2.90

2.19

0.90

0.71

0.18

30

3.76

1.97

0.58

0.76

0.24

45

4.47

2.64

0.43

0.75

0.20

60

5.45

4.31

0.61

0.55

0.45

75

6.82

4.10

0.66

0.63

0.33

90

3.51

5.33

0.82

0.82

0.43

105

5.16

4.26

0.84

0.91

0.43

120

8.62

3.90

0.82

1.19

0.29

135

6.28

3.28

0.85

1.21

0.67

150

5.09

4.54

0.85

0.95

0.72
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165

3.00

4.80

0.85

0.63

0.80

180

2.88

4.81

0.85

0.74

0.80

195

2.95

4.81

0.85

0.74

0.80

210

2.95

4.81

0.85

0.74

0.80

225

2.95

4.81

0.85

0.74

0.80

Table 7. Standard deviations in the corresponding percentage increase in mean sphere size
observed.

E. Statistical analysis for Viability data
Data: Percentage Viability: Within group analysis using ANOVA-one way classification
Day 1
Day 7 Day 14 Day 21
99.3631 93.75 90.125
81.25
99.3197 93.75
90.11
81.251
99.5413 93.72
90.12 81.1457
99.5495 93.73 90.125
81.25
85.4167 93.79
90.2
81.252
99.3827 93.75 90.125 81.246
99.4398 93.75 90.125
81.25
99.5614 93.75
90.11
81.245
99.375 93.751 89.99
81.93
99.4169 93.75 90.125
81.25

Table 8. Percentage viability observed for n=10 emulsion samples for Day 1, Day 7, Day 14 and
Day 21
H0: There is no significant difference between the average percentage viability with respect to
time (in Days)
H1: Not H0
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Between
Groups
Within Groups
Total

ANOVA
Percentage Viability
Degrees
Sum of
of
Squares
Freedom Mean Square
F
1516.519
3
505.506
102.531
177.491
1694.009

36
39

p-value
.000

4.930

Table 9. One way ANOVA analysis table
Conclusion: Reject H0, since p-value < 0.05 (Level of Significance). Hence, there is a
significant difference between Percent Viability with respect to time (in days).
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Multiple Comparisons
Dependent Variable: Percentage Viability
Bonferroni Test (Pair wise Tests)
95% Confidence Interval

Mean
(I) Time In Days

(J) Time In Days

1

Std. Error

Sig.

Lower Bound

Upper Bound

7

4.28751

*

.99300

.001

1.5151

7.0600

14

7.92111*

21
7

1
14
21

14

1
7

21

Difference (I-J)

.99300

.000

5.1487

10.6936

*

.99300

.000

13.9572

19.5021

*

.99300

.001

-7.0600

-1.5151

*

16.72964
-4.28751
3.63360

.99300

.005

.8612

6.4060

*

.99300

.000

9.6697

15.2146

-7.92111

*

.99300

.000

-10.6936

-5.1487

-3.63360

*

.99300

.005

-6.4060

-.8612

*

.99300

.000

6.0361

11.5810

12.44213

21

8.80853

1

-16.72964*

.99300

.000

-19.5021

-13.9572

7

*

.99300

.000

-15.2146

-9.6697

.99300

.000

-11.5810

-6.0361

14

-12.44213
-8.80853

*

*. The mean difference is significant at the 0.05 level.

Table 10. Bonferroni pair wise tests comparison of percentage viability as observed between
different time points.
Conclusion:
1. There is a significant difference in the average percentage viability between Day1 and
Day 7, Day 14 and Day 21.
2. There is a significant difference in the average percentage viability between Day 7 and
Day 14 and Day 21.
3. There is a significant difference in the average percentage viability between Day 14 and
Day 21.
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